Melatonin and Nighttime Blood Pressure: Formulation Matters, but Evidence Is Still Small
Review controlled-release melatonin blood-pressure trials, immediate-release differences, ambulatory monitoring, safety, and interaction limits.

Small trials suggest controlled-release—not immediate-release—melatonin may lower nighttime pressure, but evidence is low quality and does not prove cardiovascular benefit.
Night pressure is a specific endpoint
Blood pressure normally follows a daily rhythm and often falls during sleep. Some people have nocturnal hypertension or a nondipping pattern linked with higher risk. These patterns require ambulatory monitoring; a daytime office reading cannot identify them reliably.
A supplement claim about nighttime pressure should not be generalized to all hypertension. Lowering an asleep reading is also not direct proof of fewer heart attacks or strokes.

An early crossover trial found a reduction
A double-blind crossover trial in 16 men with untreated hypertension tested 2.5 milligrams of melatonin one hour before sleep for three weeks. Repeated dosing reduced asleep systolic pressure by about 6 mm Hg and diastolic pressure by about 4 mm Hg, while a single dose did not.
The sample was extremely small and included only men. The result is hypothesis-supporting, not a treatment recommendation. Short duration also leaves long-term benefit and safety unanswered.
Controlled-release results differ from immediate release
A 2011 meta-analysis of seven trials found no significant overall effect when formulations were combined. In subgroup analysis, controlled-release melatonin lowered nocturnal systolic and diastolic pressure, while immediate-release products did not.
A later review of four hypertension trials rated the evidence low to very low and found only one study at low risk of bias. Formulation, timing, and release pattern appear important, so research on one product should not validate every melatonin gummy.
A treated-hypertension trial
A randomized study in 38 people with confirmed nocturnal hypertension tested 2 milligrams of controlled-release melatonin for four weeks alongside stable medication. Nighttime systolic and diastolic pressure fell compared with placebo.
This add-on design did not test melatonin as a replacement for antihypertensive therapy. Participants had a documented nocturnal pattern, which ordinary supplement users may not have.
Product labeling is unreliable
Melatonin supplements can vary from their labeled amount, and immediate-release, sustained-release, and controlled-release products are not interchangeable. Gummies may add sugar and encourage casual dose escalation.
Choose a product with independent quality testing when possible. More milligrams do not necessarily produce better sleep or pressure control, and morning grogginess may worsen with higher doses.

Safety and interactions
NCCIH considers short-term use reasonably safe for most adults but notes limited long-term safety data. Drowsiness, headache, dizziness, and vivid dreams can occur. People taking blood thinners or epilepsy medicines need medical supervision.
Melatonin may add to sedatives, alcohol, cannabis, or sleep medicines and can impair driving. Pregnancy, breastfeeding, autoimmune conditions, and complex medication regimens warrant individualized guidance.
The appropriate conclusion
Controlled-release melatonin is an interesting candidate for documented nocturnal hypertension, but current trials are too small and short to establish routine cardiovascular treatment. No reviewed study proved fewer cardiovascular events.
Do not use melatonin to adjust blood-pressure medicine. If nighttime pressure is a concern, confirm it with appropriate monitoring and discuss sleep apnea, medication timing, kidney disease, and other causes with a clinician.
Sleep apnea can hide behind nocturnal hypertension
Obstructive sleep apnea can produce repeated oxygen drops, sympathetic activation, fragmented sleep, and difficult nighttime blood-pressure patterns. Melatonin does not open a blocked airway. Loud snoring, witnessed pauses, gasping, morning headaches, and marked daytime sleepiness warrant evaluation rather than escalating a sleep supplement.
Treating sleep apnea may improve symptoms and cardiovascular risk management while addressing a cause that a capsule cannot. A favorable short melatonin trial in selected hypertension patients does not show benefit for untreated apnea. Nocturnal pressure should be interpreted alongside sleep history, medication timing, and kidney or endocrine conditions.
Timing and circadian goals
Melatonin is a time signal as well as a sedating supplement. The optimal timing depends on whether the goal is shifting the body clock, supporting sleep onset, or testing controlled release for overnight exposure. Taking it at random times can worsen circadian misalignment.
Bright evening light, irregular wake times, and late caffeine can counteract the intended signal. A lower, well-timed dose may be more rational than a larger dose. Blood-pressure treatment, however, should not be adjusted from sleep response alone, and ambulatory monitoring is needed to verify any nocturnal effect.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.